Published in Biologics on May 03, 2013
Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema | NCT01574248
Successful use of daily intravenous infusion of C1 esterase inhibitor concentrate in the treatment of a hereditary angioedema patient with ascites, hypovolemic shock, sepsis, renal and respiratory failure. Allergy Asthma Clin Immunol (2014) 0.77
Factor XII-Driven Inflammatory Reactions with Implications for Anaphylaxis. Front Immunol (2017) 0.75
Pediatric hereditary angioedema: an update. F1000Res (2017) 0.75
A BIOCHEMICAL ABNORMALITY IN HEREDIATRY ANGIONEUROTIC EDEMA: ABSENCE OF SERUM INHIBITOR OF C' 1-ESTERASE. Am J Med (1963) 5.19
Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol (1991) 3.60
Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema. J Allergy Clin Immunol (2004) 3.30
Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med (1976) 3.10
Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol (2004) 3.07
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med (2010) 2.98
Clinical practice. Hereditary angioedema. N Engl J Med (2008) 2.95
Hereditary angioedema: a broad review for clinicians. Arch Intern Med (2001) 2.92
2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol (2010) 2.75
Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol (1991) 2.72
Hereditary angioedema with normal C1-inhibitor activity in women. Lancet (2000) 2.65
Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) (1992) 2.51
Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med (2006) 2.35
Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med (2010) 2.28
Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc (2000) 2.09
C1 inhibitor deficiency: consensus document. Clin Exp Immunol (2005) 2.07
Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med (2010) 2.07
Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy (2011) 2.00
Hereditary angio-oedema. Lancet (2012) 1.95
Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis (2011) 1.94
Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol (2009) 1.94
Hereditary angioedema. N Engl J Med (1996) 1.85
Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest (2002) 1.82
C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol (1988) 1.80
C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med (2009) 1.63
The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc (2010) 1.58
Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. J Allergy Clin Immunol (2000) 1.53
Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol (2007) 1.52
HAE international home therapy consensus document. Allergy Asthma Clin Immunol (2010) 1.42
Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. Ann Emerg Med (2010) 1.35
Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol (2010) 1.35
The pathophysiology of hereditary angioedema. Clin Immunol (2005) 1.34
Bradykinin-mediated angioedema. N Engl J Med (2002) 1.28
Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol (2011) 1.28
Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol (2003) 1.27
Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia. Pharmacoeconomics (2011) 1.12
Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol (2010) 1.12
Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. PLoS One (2013) 1.05
EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol (2010) 1.04
Sonographic findings in abdominal hereditary angioedema. J Clin Ultrasound (1999) 0.99
Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks. Ann Allergy Asthma Immunol (2009) 0.98
On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience. Allergy Asthma Clin Immunol (2010) 0.95
Icatibant. Drugs (2010) 0.94
Hereditary angioedema: an infrequent cause of abdominal pain with ascites. Am J Gastroenterol (1995) 0.92
Successful treatment of acquired C1 inhibitor deficiency with icatibant. Clin Exp Dermatol (2010) 0.91
Hereditary angioedema in women. Allergy Asthma Clin Immunol (2010) 0.91
An evidence-based review of the potential role of icatibant in the treatment of acute attacks in hereditary angioedema type I and II. Core Evid (2012) 0.91
Hereditary angioedema: beyond international consensus - circa December 2010 - The Canadian Society of Allergy and Clinical Immunology Dr. David McCourtie Lecture. Allergy Asthma Clin Immunol (2011) 0.90
Hereditary angioedema with normal C1 inhibitor activity including hereditary angioedema with coagulation factor XII gene mutations. Immunol Allergy Clin North Am (2006) 0.90
Hypertension and the bradykinin system. Curr Hypertens Rep (2009) 0.88
Functional C1-inhibitor diagnostics in hereditary angioedema: assay evaluation and recommendations. J Immunol Methods (2008) 0.87
In vitro effects of HOE 140 in human bronchial and vascular tissue. Eur J Pharmacol (1995) 0.83
Cardiovascular activities of the bradykinin system. ScientificWorldJournal (2008) 0.82
One hypovolaemic shock…two kinin pathway abnormalities. Intensive Care Med (2011) 0.81
Successful treatment of an acute attack of acquired angioedema with the bradykinin-B2-receptor antagonist icatibant. J Eur Acad Dermatol Venereol (2011) 0.81
Icatibant in hereditary angioedema: news and challenges. Expert Rev Clin Immunol (2011) 0.80
Icatibant: a novel approach to the treatment of angioedema related to the use of angiotensin-converting enzyme inhibitors. Am J Emerg Med (2011) 0.79
Meeting the challenges and burdens associated with hereditary angioedema. Manag Care (2011) 0.77
Hereditary angioedema. Complex symptoms can make diagnosis difficult. Postgrad Med (1998) 0.76
A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. J Med Chem (2005) 2.52
Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med (2010) 2.28
Molecular shape and medicinal chemistry: a perspective. J Med Chem (2010) 1.91
Gaussian docking functions. Biopolymers (2003) 1.82
Small molecule shape-fingerprints. J Chem Inf Model (2005) 1.42
The SAMP1 solvation challenge: further lessons regarding the pitfalls of parametrization. J Phys Chem B (2009) 0.99
SAMPL2 and continuum modeling. J Comput Aided Mol Des (2010) 0.95
Mediators of anaphylaxis. Immunol Allergy Clin North Am (2007) 0.93
Molecular shape and electrostatics in the encoding of relevant chemical information. J Comput Aided Mol Des (2005) 0.85
Potent fibrinolysis inhibitor discovered by shape and electrostatic complementarity to the drug tranexamic acid. J Med Chem (2013) 0.83
Immunomodulation: the future of allergy and asthma treatment. Curr Opin Allergy Clin Immunol (2004) 0.80
Modular, gold-catalyzed approach to the synthesis of lead-like piperazine scaffolds. Org Lett (2013) 0.78
Using electronic polarization from the internal continuum (EPIC) for intermolecular interactions. J Comput Chem (2010) 0.78
Levocetirizine: the allergist's arsenal grows larger. Expert Opin Pharmacother (2004) 0.78
Ketotifen in the management of chronic urticaria: resurrection of an old drug. Ann Allergy Asthma Immunol (2013) 0.77
Mechanisms of IgE-mediated allergic reactions. Clin Allergy Immunol (2004) 0.75
A modular lead-oriented synthesis of diverse piperazine, 1,4-diazepane and 1,5-diazocane scaffolds. Org Biomol Chem (2014) 0.75
Life with hereditary angioedema: then and now. Postgrad Med (2012) 0.75
Role of epigenetics and DNA-damage in asthma. Curr Opin Allergy Clin Immunol (2017) 0.75